• 1. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

6-Bromo-1-methyl-1H-indazole-4-carboxylic acid (CAS No. 1245465-69-3): A Comprehensive Overview

6-Bromo-1-methyl-1H-indazole-4-carboxylic acid (CAS No. 1245465-69-3) is a specialized organic compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This brominated indazole derivative is known for its unique structural features and potential applications in drug discovery. With the increasing demand for novel heterocyclic compounds in modern therapeutics, understanding the properties and uses of this molecule becomes crucial for researchers and industry professionals.

The molecular structure of 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid combines three important functional groups: a bromo substituent at the 6-position, a methyl group at the 1-position, and a carboxylic acid moiety at the 4-position of the indazole core. This strategic arrangement of substituents makes it particularly valuable as a building block in organic synthesis. Recent trends in pharmaceutical development show growing interest in such functionalized indazole derivatives, especially for their potential in creating kinase inhibitors and other targeted therapies.

From a chemical perspective, 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid typically appears as a white to off-white crystalline powder. It demonstrates moderate solubility in polar organic solvents like dimethyl sulfoxide (DMSO) and dimethylformamide (DMF), but limited solubility in water. These solubility characteristics are important considerations when planning synthetic routes or biological assays. The compound's stability under various conditions makes it suitable for diverse synthetic applications, a feature that has been highlighted in several recent publications on heterocyclic compound synthesis.

The primary application of 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid lies in its role as a key intermediate in pharmaceutical research. Many researchers are investigating its potential in developing new small molecule drugs, particularly in oncology and inflammation-related therapies. The indazole scaffold is known to interact with various biological targets, and the presence of the bromo substituent offers opportunities for further functionalization through cross-coupling reactions, a topic that frequently appears in current medicinal chemistry literature.

Recent advancements in cancer drug discovery have brought increased attention to compounds like 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid. The molecule's ability to serve as a precursor for protein kinase inhibitors aligns with current trends in targeted cancer therapies. Pharmaceutical companies and academic labs are actively exploring its derivatives as potential candidates for tyrosine kinase inhibition, a hot topic in contemporary drug development discussions.

The synthesis of 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid typically involves multi-step organic transformations starting from commercially available indazole precursors. Modern synthetic approaches often employ palladium-catalyzed coupling reactions for introducing the bromo substituent, followed by careful methylation and oxidation steps to install the remaining functional groups. These methods have been optimized in recent years to improve yields and reduce environmental impact, reflecting the growing emphasis on green chemistry principles in pharmaceutical manufacturing.

Quality control of 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid is typically performed using advanced analytical techniques such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry. The compound generally shows high purity levels (>95%) when properly synthesized and purified. These analytical specifications are crucial for researchers who require consistent quality in their synthetic work, especially when developing potential drug candidates.

From a commercial perspective, the demand for 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid has been steadily increasing, particularly from contract research organizations and academic institutions engaged in drug discovery programs. Suppliers typically offer the compound in various quantities, ranging from milligram-scale for initial research to kilogram quantities for larger-scale development projects. The current market trend shows growing interest in custom synthesis services for such specialized intermediates, as pharmaceutical companies seek to accelerate their discovery pipelines.

Storage and handling of 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid require standard laboratory precautions. The compound should be kept in a cool, dry environment, protected from light and moisture to maintain stability over extended periods. While not classified as highly hazardous, proper laboratory safety protocols should always be followed when working with this or any other organic compound, including the use of personal protective equipment and adequate ventilation.

The future outlook for 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid appears promising, given the continued expansion of research into indazole-based therapeutics. As drug discovery efforts increasingly focus on targeted molecular therapies, the need for versatile building blocks like this compound is expected to grow. Ongoing research may uncover additional applications beyond its current uses, potentially in areas such as neurodegenerative disease treatment or antimicrobial development.

For researchers interested in working with 6-Bromo-1-methyl-1H-indazole-4-carboxylic acid, it's recommended to consult recent scientific literature for the latest synthetic methodologies and application studies. Many publications have explored the compound's potential in creating novel bioactive molecules, particularly in the context of structure-activity relationship studies. Keeping abreast of these developments can help maximize the utility of this valuable chemical intermediate in various research programs.

• 885523-43-3(4-Bromo-1H-indazole-6-carboxylic acid)
• 1071433-06-1(2-methyl-2H-indazole-4-carboxylic acid)
• 1071428-42-6(Methyl 1-methyl-1H-indazole-4-carboxylate)
• 1245465-67-1(Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate)
• 1197943-94-4(2-methyl-2H-indazole-5-carboxylic acid)
• 1071433-05-0(1-Methyl-1H-indazole-4-carboxylic acid)
• 885523-08-0(6-Bromo-1H-indazole-4-carboxylic acid)
• 1031417-46-5(2-Methyl-2H-indazole-6-carboxylic acid)
• 1031417-77-2(1-Methyl-1H-indazole-6-carboxylic acid)
• 1176754-31-6(1-Methyl-1H-indazole-5-carboxylic acid)